Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Hematologic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Small Intestinal Neuroendocrine Tumor 1Papillomavirus Infections 1Pancreatic Adenocarcinoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Leukemia 1Heart Failure 1HER2-positive Breast Cancer 1Cystic Fibrosis 1Cardiomyopathies 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Electronic Health Records × Clear all
NCT04445870 2022-07-11

ONCOCARE-COV

CHU de Reims

Completed
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡